Element Biosciences Inc., developer of a new and disruptive DNA sequencing platform, today announced the commercial launch of the Element AVITI System, a benchtop sequencer offering an unrivaled combination of performance, cost, and flexibility. Element’s proprietary Avidity Sequencing chemistries enables exceptional accuracy and cost efficiency that is unmatched by other benchtop systems. The AVITI System operates two random access flow cells that enable independent run start flexibility of each flow cell, and the AVITI operating software features tunable read throughput control for additional run time flexibility.
“With the launch of our AVITI System, Element is delivering on its vision to dramatically expand access to high quality, low cost, easy-to-use genomics tools,” said Molly He, Ph.D., CEO and co-founder of Element Biosciences. “And with the recent Loop Genomics acquisition, we will offer both short and long-read capabilities on a single platform. AVITI will bring the ultimate freedom and flexibility for users.”
“There is often a sacrifice between accuracy, throughput, and costs. With Element’s new benchtop sequencer, researchers will not be forced to make those compromises. They will receive industry leading quality and cost at a throughput level that more closely matches the needs of most applications,” said John Stuelpnagel, chairman of Element Biosciences.
Element has released seven application and technology notes along with five sequencing datasets for download that cover human whole genome, bacterial whole genome, and RNA-Seq assays using the Element AVITI System.
Access these assets and learn more about AVITI here.
Equiva, a leader in digital patient engagement and health relationship management, extends thanks to their colleague, Eyal Shemesh, MD, Professor of Pediatrics and Psychiatry at the Icahn School of Medicine at Mount Sinai, and chief of the Division of Developmental and Behavioral Pediatrics.
On Wednesday, March 30, Dr. Shemesh will join a line-up of expert panelists for a session titled Building a Better Patient Engagement Platform, one of three sessions included in a half-day Technology Now Online Summit from HealthLeaders. Other panelists include Jeff Johnson, Banner Health’s VP of Innovation and Digital Business, and Bilal Naved, Co-founder and COO of Clearstep. HealthLeaders’s senior tech editor Erick Wicklund will moderate. Other sessions focus on the use of AI to improve care management and technology’s facilitation of chronic care management.
Dr. Shemesh and his were recipients of an $860,000 award from the FCC’s COVID-19 Telehealth program, and used funds to ensure continued care for clinic patients during the pandemic by sending tablet devices to family’s homes. To overcome barriers for patients with limited technology access and literacy, Equiva tablets were preconfigured with one-touch access to telehealth visits, patient education materials and survey tools. Dr. Shemesh has a long history of research in leveraging digital tools to enhance patient care.
Register here for this no-cost event.
Healthmine developed a free resource to help Medicare Advantage plans evaluate their reward and incentives programs. Download the worksheet to score your program using Healthmine’s methodology across five critical touchpoints.
Click here to download now.
UniDoc Health Corp., a telehealth business, has commenced pilot trials with three commercial pharmacies in Ontario, Canada as part of a collaboration with OnPharm-United, a network of independent pharmacies in Canada.
If the pilot is successful, OnPharm-United will offer UniDoc’s virtual care solutions model kiosks to its network of pharmacies in Ontario.
To read more, click here.
House Rx, a health tech startup seeking to improve affordability and patient access to specialty medications, has secured $25 million as part of a Series A funding round led by Bessemer Venture Partners,
House Rx’s technology platform and pharmacy service help specialty practices to offer medically integrated dispensing, so that patients can receive both their physician and pharmacy care from one team, collaborating on a unified technology platform. After launching in March last year, House Rx has partnered with four medical specialty practices and 30 prescribers in California and Washington.
Specialty medications can include treatments for cancers, rheumatic diseases and other chronic and acute conditions, are some of the most expensive drugs available. Unlike infused therapies which are administered in the clinics, the burden of specialty medication access and adherence typically falls on patients, who often need to battle several large bureaucracies to gain access to their medications.
To read more, click here.
Picture: akindo, Getty Images
